About Lytica Therapeutics
Lytica Therapeutics is a company based in Cambridge (United States) founded in 2019.. Lytica Therapeutics has raised $5.82 million across 4 funding rounds from investors including CARB-X. Lytica Therapeutics offers products and services including SPACE Platform and SIP Antibody Co-conjugates. Lytica Therapeutics operates in a competitive market with competitors including Orakl Oncology, Oncodesign, LumaBridge, Orange Grove Bio LLC and Axios Biosciences, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lytica Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.82 M (USD)
in 4 rounds
-
Latest Funding Round
$6 M (USD), Debt – Conventional
Feb 28, 2025
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lytica Therapeutics
Lytica Therapeutics offers a comprehensive portfolio of products and services, including SPACE Platform and SIP Antibody Co-conjugates. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables modular antibody functionalization for enhanced oncology treatments
Increases ADC internalization and efficacy for cancer applications
Unlock access to complete
Unlock access to complete
Scientific Team
6 people
Operations Team
3 people
Leadership Team
2 people
Senior Team
1 people
Unlock access to complete
Funding Insights of Lytica Therapeutics
Lytica Therapeutics has successfully raised a total of $5.82M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Conventional — $6.0M
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Debt – Conventional - Lytica Therapeutics | Valuation |
investors |
|
| Jul, 2024 | Amount | Series A - Lytica Therapeutics | Valuation |
investors |
|
| Feb, 2024 | Amount | Series A - Lytica Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lytica Therapeutics
Lytica Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lytica Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lytica Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lytica Therapeutics Comparisons
Competitors of Lytica Therapeutics
Lytica Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, LumaBridge, Orange Grove Bio LLC and Axios Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
|
|
| domain | founded_year | HQ Location |
Preclinical assessment services for anti-cancer therapies are provided.
|
|
| domain | founded_year | HQ Location |
Provider of oncology clinical research, regulatory affairs, and data management services
|
|
| domain | founded_year | HQ Location |
Provider of preclinical development services
|
|
| domain | founded_year | HQ Location |
Creates innovative platforms for anti-cancer drug development.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lytica Therapeutics
Frequently Asked Questions about Lytica Therapeutics
When was Lytica Therapeutics founded?
Lytica Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Lytica Therapeutics located?
Lytica Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Lytica Therapeutics?
Jim LaTorre is the current CEO of Lytica Therapeutics.
Is Lytica Therapeutics a funded company?
Lytica Therapeutics is a funded company, having raised a total of $5.82M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.07M, raised on Feb 18, 2020.
What does Lytica Therapeutics do?
Lytica Therapeutics was founded in 2019 and is headquartered in Cambridge, United States. Operations are centered on the development of therapeutic drugs within the biotechnology sector. Research and innovation efforts are directed toward creating treatments for various health conditions. The company is led by CEO Jim LaTorre, with activities focused on advancing pharmaceutical solutions in a competitive industry landscape.
Who are the top competitors of Lytica Therapeutics?
Lytica Therapeutics's top competitors include Oncodesign, Orakl Oncology and Orange Grove Bio LLC.
What products or services does Lytica Therapeutics offer?
Lytica Therapeutics offers SPACE Platform and SIP Antibody Co-conjugates.
Who are Lytica Therapeutics's investors?
Lytica Therapeutics has 1 investor. Key investors include CARB-X.